Buscar
01/08/2022
BNIP3 Is Involved in Muscle Fiber Atrophy in Late-Onset Pompe Disease Patients
Carrasco-Rozas, A, Fernandez-Simon, E, Suarez-Calvet, X, Pinol-Jurado, P, Alonso-Perez, J, de Luna, N, Schoser, B, Meinke, P, Dominguez-Gonzalez, C, Hernandez-Lain, A, Paradas, C, Rivas, E, Illa, I, Olive, M, Gallardo, E, Diaz-Manera, J. BNIP3 Is Involved in Muscle Fiber Atrophy in Late-Onset Pompe Disease Patients. AMERICAN JOURNAL OF PATHOLOGY. 2022; 192(8)DOI:10.1016/j.ajpath.2022.05.003. PMID:35605642. IF:6.000(Q1/2D).
01/01/2022
Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia
Caballero-Ávila M., Álvarez-Velasco R., Moga E., Rojas-Garcia R., Turon-Sans J., Querol L., Olivé M., Reyes-Leiva D., Illa I., Gallardo E., Cortés-Vicente E.. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. NEUROMUSCULAR DISORDERS. 2022; 32(8)DOI:10.1016/j.nmd.2022.06.006. PMID:35811274. IF:2.800(Q3/6D).
01/01/2022
Azathioprine therapy induces selective NK cell depletion and IFN-? deficiency predisposing to herpesvirus reactivation
Ingelfinger F., Sparano C., Bamert D., Reyes-Leiva D., Sethi A., Rindlisbacher L., Zwicky P., Kreutmair S., Widmer C.C., Mundt S., Cortés-Vicente E., Tugues S., Becher B., Schreiner B.. Azathioprine therapy induces selective NK cell depletion and IFN-? deficiency predisposing to herpesvirus reactivation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2022; 151(1)DOI:10.1016/j.jaci.2022.09.010. PMID:36122787. IF:14.200(Q1/1D).
01/01/2022
Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management
Bolano-Diaz, C, Diaz-Manera, J. Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management. Therapeutics and Clinical Risk Management. 2022; 18DOI:10.2147/TCRM.S334232. PMID:36536827. IF:2.800(Q3/6D).